JBIO - Aerovate Therapeutics, Inc.

25.21
-0.170   -0.674%

Share volume: 683,877
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$25.38
-0.17
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 19%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.28%
1 Month
90.12%
3 Months
66.07%
6 Months
152.10%
1 Year
826.84%
2 Year
18.92%
Key data
Stock price
$25.21
P/E Ratio 
N/A
DAY RANGE
$24.58 - $25.85
EPS 
-$2.91
52 WEEK RANGE
$2.63 - $26.33
52 WEEK CHANGE
$840.67
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
49.316 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$720,994
AVERAGE 30 VOLUME 
$696,252
Company detail
CEO: Timothy P. Noyes
Region: US
Website: aerovatetx.com
Employees: 20
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aerovate Therapeutics, Inc. focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company is advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

Recent news